Menu
Recruiting NCT07418385

Voluntary HIV Screening in the General Population in France

— Observational Human Immunodeficiency Virus (HIV)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: data collections.
Who it may be relevant to
Registry conditions: Human Immunodeficiency Virus (HIV). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Since 2020, an increase in positive screenings for sexually transmitted infections, including HIV, has been observed. Voluntary early screening plays an important role in the national strategy for HIV care in France. There are currently several methods that allow patients to undergo voluntary screening.

Detailed description

Objectives

The main objective is to describe the voluntary HIV screening methods used by the general population in France.

Interventions

  • Other data collections
    data collections

Primary outcome measures

  • The method(s) used for undergoing voluntary HIV testing questionnaire [Time frame: Day 0]

Eligibility criteria

Inclusion criteria

  • 18 years of age or older
  • Male or female
  • Regardless of sexual orientation
  • Whether or not they have previously undergone voluntary HIV testing
  • Agreeing to participate in the study.

Exclusion criteria

  • Minors
  • Refusing to participate in the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-only

Study locations

France · 1 center
  • Ufr Medecine Urca — Reims

Identifiers

NCT: NCT07418385 · 2025_RIPH_08_DEPISTAGEVIH

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗